Evidence map›Paper›PMID 22187655›Full record

ArticleJournal of lipids2012

Nuclear receptors in nonalcoholic Fatty liver disease.

Jorge A López-Velázquez, Luis D Carrillo-Córdova, Norberto C Chávez-Tapia, Misael Uribe, Nahum Méndez-Sánchez

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipids, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials.International journal of translational medicine (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. HepaticeLife · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Endocrine-disrupting chemicals and fatty liver disease.Nature reviews. Endocrinology · 2017
    Review
  14. Article
  15. Article
  16. Nuclear receptors and nonalcoholic fatty liver disease.Biochimica et biophysica acta · 2016
    Review
  17. Article
  18. Review
  19. FXR signaling in the enterohepatic system.Molecular and cellular endocrinology · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jorge A López-VelázquezLiver Research Unit, Medica Sur Clinic & Foundation, Puente de Piedra 150, Colonia Toriello Guerra, 14050 Tlalpan, Mexico City, Mexico.
Luis D Carrillo-Córdova
Norberto C Chávez-Tapia
Misael Uribe
Nahum Méndez-Sánchez
Hospital Médica Sur · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear receptors comprise a superfamily of ligand-activated transcription factors that are involved in important aspects of hepatic physiology and pathophysiology. There are about 48 nuclear receptors in the human. These nuclear receptors are regulators of many hepatic processes including hepatic lipid and glucose metabolism, bile acid homeostasis, drug detoxification, inflammation, regeneration, fibrosis, and tumor formation. Some of these receptors are sensitive to the levels of molecules that control lipid metabolism including fatty acids, oxysterols, and lipophilic molecules. These receptors direct such molecules to the transcriptional networks and may play roles in the pathogenesis and treatment of nonalcoholic fatty liver disease. Understanding the mechanisms underlying the involvement of nuclear receptors in the pathogenesis of nonalcoholic fatty liver disease may offer targets for the development of new treatments for this liver disease.

Identifiers

PMID22187655
PMCPMC3236492
OpenAlexW2082815388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.